European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) sees rapid growth
The seventh plenary meeting of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) has heard that the network has grown considerably over the past few months, with over 100 resources from 17 different European countries now registered.
The meeting, held today at the European Medicines Agency, reported that ENCePP has been attracting interest from an increasing number of centres, networks and owners of data sources that have a specific focus on pharmacovigilance, pharmacoepidemiology and post-authorisation research.
ENCePP is a network that aims to strengthen the monitoring of authorised medicines in Europe. It does this by facilitating the conduct of multi-centre, independent, post-authorisation studies.
With a record attendance from ENCePP partners, today's meeting featured sessions on the possible interaction between ENCePP and health-technology-assessment bodies, methodology and the definition of non-interventional trials.
Representatives from the United States Food and Drug Administration and Health Canada also attended, providing updates on their national initiatives on the safety monitoring of medicines after authorisation: Sentinel in the United States and the Drug Safety and Effectiveness Network in Canada.
On Wednesday 29 June, a meeting between the ENCePP Steering Group and representatives from scientific journals preceded the main plenary session. The meeting raised awareness of ENCePP initiatives and enabled a discussion on the interaction between journals, publication, medicines regulation and ENCePP.